|
|
Everyone has a donor: contribution of the Chinese experience to global practice of haploidentical hematopoietic stem cell transplantation |
Meng Lv1, Yingjun Chang1, Xiaojun Huang1,2() |
1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China 2. Peking-Tsinghua Center for Life Sciences, Beijing 100044, China |
|
|
Abstract Human leukocyte antigen (HLA)-matched donors for hematopoietic stem cell transplantation (HSCT) have long been scarce in China. Haploidentical (haplo) donors are available for the vast majority of patients, but toxicity has limited this approach. Three new approaches for haplo-HSCT originated from Italy, China, and USA in 1990 and have been developed to world-renowned system up to now. The Chinese approach have been greatly improved by implementing new individualized conditioning regimens, donor selection based on non-HLA systems, risk-directed strategies for graft-versus-host disease and relapse, and infection management. Haplo-HSCT has exhibited similar efficacy to HLA-matched HSCT and has gradually become the predominant donor source and the first alternative donor choice for allo-HSCT in China. Registry-based analyses and multicenter studies adhering to international standards facilitated the transformation of the unique Chinese experience into an inspiration for the refinement of global practice. This review will focus on how the new era in which “everyone has a donor” will become a reality in China.
|
Keywords
haploidentical hematopoietic stem cell transplantation
conditioning
graft-versus-host disease
relapse
infection
donor selection
|
Corresponding Author(s):
Xiaojun Huang
|
Just Accepted Date: 20 December 2017
Online First Date: 18 April 2018
Issue Date: 12 March 2019
|
|
1 |
M Lv, XJ Huang. Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go. J Hematol Oncol 2012; 5(1): 10
https://doi.org/10.1186/1756-8722-5-10
pmid: 22424172
|
2 |
LP Xu, DP Wu, MZ Han, H Huang, QF Liu, DH Liu, ZM Sun, LH Xia, J Chen, HX Wang, C Wang, CF Li, YR Lai, JM Wang, DB Zhou, H Chen, YP Song, T Liu, KY Liu, XJ Huang. A review of hematopoietic cell transplantation in China: data and trends during 2008–2016. Bone Marrow Transplant 2017; 52(11):1512–1518
https://doi.org/10.1038/bmt.2017.59
pmid: 28436973
|
3 |
Y Reisner, D Hagin, MF Martelli. Haploidentical hematopoietic transplantation: current status and future perspectives. Blood 2011; 118(23): 6006–6017
https://doi.org/10.1182/blood-2011-07-338822
pmid: 21921045
|
4 |
A Velardi. Haplo-BMT: which approach? Blood 2013; 121(5): 719–720
https://doi.org/10.1182/blood-2012-12-469981
pmid: 23372150
|
5 |
R Szydlo, JM Goldman, JP Klein, RP Gale, RC Ash, FH Bach, BA Bradley, JT Casper, N Flomenberg, JL Gajewski, E Gluckman, PJ Henslee-Downey, JM Hows, N Jacobsen, HJ Kolb, B Lowenberg, T Masaoka, PA Rowlings, PM Sondel, DW van Bekkum, JJ van Rood, MR Vowels, MJ Zhang, MM Horowitz. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997; 15(5): 1767–1777
https://doi.org/10.1200/JCO.1997.15.5.1767
pmid: 9164184
|
6 |
EJ Fuchs. Haploidentical transplantation for hematologic malignancies: where do we stand? Hematology Am Soc Hematol Educ Program 2012; 2012: 230–236
|
7 |
CG Kanakry, EJ Fuchs, L Luznik. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol 2016; 13(1): 10–24
https://doi.org/10.1038/nrclinonc.2015.128
pmid: 26305035
|
8 |
J Apperley, D Niederwieser, XJ Huang, A Nagler, E Fuchs, J Szer, Y Kodera. Haploidentical hematopoietic stem cell transplantation: a global overview comparing Asia, the European Union, and the United States. Biol Blood Marrow Transplant 2016; 22(1): 23–26
https://doi.org/10.1016/j.bbmt.2015.11.001
pmid: 26551633
|
9 |
F Aversa, A Tabilio, A Terenzi, A Velardi, F Falzetti, C Giannoni, R Iacucci, T Zei, MP Martelli, C Gambelunghe, et al.. Successful engraftment of T-cell-depleted haploidentical “three-loci” incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994; 84(11): 3948–3955
pmid: 7524753
|
10 |
F Aversa, A Tabilio, A Velardi, I Cunningham, A Terenzi, F Falzetti, L Ruggeri, G Barbabietola, C Aristei, P Latini, Y Reisner, MF Martelli, R Felicini, F Falcinelli, A Carotti, K Perruccio, S Ballanti, A Santucci, C Gambelunghe. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339(17): 1186–1193
https://doi.org/10.1056/NEJM199810223391702
pmid: 9780338
|
11 |
F Aversa, A Terenzi, A Tabilio, F Falzetti, A Carotti, S Ballanti, R Felicini, F Falcinelli, A Velardi, L Ruggeri, T Aloisi, JP Saab, A Santucci, K Perruccio, MP Martelli, C Mecucci, Y Reisner, MF Martelli. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23(15): 3447–3454
https://doi.org/10.1200/JCO.2005.09.117
pmid: 15753458
|
12 |
XJ Huang, YH Chen, LP Xu, YC Zhang, DH Liu, NL Guo, DP Lu. Combined transplantation of G-CSF primed allogeneic bone marrow cells and peripheral blood stem cells in treatment of severe aplastic anemia. Chin Med J (Engl) 2004; 117(4): 604–607
pmid: 15109458
|
13 |
XJ Huang, DH Liu, KY Liu, LP Xu, H Chen, W Han, YH Chen, JZ Wang, ZY Gao, YC Zhang, Q Jiang, HX Shi, DP Lu. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006; 38(4): 291–297
https://doi.org/10.1038/sj.bmt.1705445
pmid: 16883312
|
14 |
L Luznik, LW Engstrom, R Iannone, EJ Fuchs. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol Blood Marrow Transplant 2002; 8(3): 131–138
https://doi.org/10.1053/bbmt.2002.v8.pm11939602
pmid: 11939602
|
15 |
L Luznik, PV O’Donnell, HJ Symons, AR Chen, MS Leffell, M Zahurak, TA Gooley, S Piantadosi, M Kaup, RF Ambinder, CA Huff, W Matsui, J Bolaños-Meade, I Borrello, JD Powell, E Harrington, S Warnock, M Flowers, RA Brodsky, BM Sandmaier, RF Storb, RJ Jones, EJ Fuchs. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14(6): 641–650
https://doi.org/10.1016/j.bbmt.2008.03.005
pmid: 18489989
|
16 |
HX Jun, CY Jun, ZX Yu. In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Haematologica 2004; 89(12): 1517–1524
pmid: 15590404
|
17 |
HX Jun, CY Jun, ZX Yu. A direct comparison of immunological characteristics of granulocyte colony-stimulating factor (G-CSF)-primed bone marrow grafts and G-CSF-mobilized peripheral blood grafts. Haematologica 2005; 90(5): 715–716
pmid: 15921400
|
18 |
YJ Chang, XJ Huang. Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers. Bone Marrow Transplant 2014; 49(7): 873–879
https://doi.org/10.1038/bmt.2014.19
pmid: 24566712
|
19 |
Y Hu, GL He, XY Zhao, XS Zhao, Y Wang, LP Xu, XH Zhang, XZ Yu, KY Liu, YJ Chang, XJ Huang. Regulatory B cells promote graft-versus-host disease prevention and maintain graft-versus-leukemia activity following allogeneic bone marrow transplantation. OncoImmunology 2017; 6(3): e1284721
https://doi.org/10.1080/2162402X.2017.1284721
pmid: 28405514
|
20 |
XS Zhao, XH Wang, XY Zhao, YJ Chang, LP Xu, XH Zhang, XJ Huang. Non-traditional CD4+CD25−CD69+ regulatory T cells are correlated to leukemia relapse after allogeneic hematopoietic stem cell transplantation. J Transl Med 2014; 12(1): 187
https://doi.org/10.1186/1479-5876-12-187
pmid: 24984576
|
21 |
SY Lu, XJ Huang, KY Liu, DH Liu, LP Xu. High frequency of CD4+CD25−CD69+ T cells is correlated with a low risk of acute graft-versus-host disease in allotransplants. Clin Transplant 2012; 26(2): E158–E167
https://doi.org/10.1111/j.1399-0012.2012.01630.x
pmid: 22507356
|
22 |
SY Lu, KY Liu, DH Liu, LP Xu, XJ Huang. High frequencies of CD62L+ naive regulatory T cells in allografts are associated with a low risk of acute graft-versus-host disease following unmanipulated allogeneic haematopoietic stem cell transplantation. Clin Exp Immunol 2011; 165(2): 264–277
https://doi.org/10.1111/j.1365-2249.2011.04418.x
pmid: 21635226
|
23 |
M Lv, XS Zhao, Y Hu, YJ Chang, XY Zhao, Y Kong, XH Zhang, LP Xu, KY Liu, XJ Huang. Monocytic and promyelocytic myeloid-derived suppressor cells may contribute to G-CSF-induced immune tolerance in haplo-identical allogeneic hematopoietic stem cell transplantation. Am J Hematol 2015; 90(1): E9–E16
https://doi.org/10.1002/ajh.23865
pmid: 25303038
|
24 |
XY Zhao, YT Wang, XD Mo, XS Zhao, YZ Wang, YJ Chang, XJ Huang. Higher frequency of regulatory T cells in granulocyte colony-stimulating factor (G-CSF)-primed bone marrow grafts compared with G-CSF-primed peripheral blood grafts. J Transl Med 2015; 13(1): 145
https://doi.org/10.1186/s12967-015-0507-z
pmid: 25948100
|
25 |
XY Zhao, LL Xu, SY Lu, XJ Huang. IL-17-producing T cells contribute to acute graft-versus-host disease in patients undergoing unmanipulated blood and marrow transplantation. Eur J Immunol 2011; 41(2): 514–526
https://doi.org/10.1002/eji.201040793
pmid: 21268020
|
26 |
XJ Huang, W Han, LP Xu, YH Chen, DH Liu, J Lu, H Chen, YC Zhang, Q Jiang, KY Liu, DP Lu. A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease. Chin Med J (Engl) 2004; 117(12): 1778–1785
pmid: 15603704
|
27 |
X Huang, Y Chen, W Han, Y Chen, H Hong, D Lu. Human leukocyte antigen mismatched hemopietic stem cell transplants for the treatment of leukemia. J Peking Univ (Health Sci) (Beijing Da Xue Xue Bao (Yi Xue Ban)) 2003; 35(2): 115–118 (in Chinese)
pmid: 12920822
|
28 |
D Liu, X Huang, K Liu, L Xu, H Chen, W Han, Y Chen, X Zhang, Q Jiang. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children. Biol Blood Marrow Transplant 2008; 14(4): 469–477
https://doi.org/10.1016/j.bbmt.2008.02.007
pmid: 18342790
|
29 |
Huang XJ, Xu LP, Liu KY, Liu DH, Chen H, Han W, Chen YH, Wang JZ, Chen Y, Zhang XH, Shi HX, Lu DP. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase. Ann Med 2008; 40(6): 444–455
https://doi.org/10.1080/07853890801908903
pmid: 18608121
|
30 |
XJ Huang, DH Liu, KY Liu, LP Xu, H Chen, W Han, YH Chen, XH Zhang, DP Lu. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 2009; 15(2): 257–265
https://doi.org/10.1016/j.bbmt.2008.11.025
pmid: 19167686
|
31 |
Y Wang, DH Liu, KY Liu, LP Xu, XH Zhang, W Han, H Chen, YH Chen, FR Wang, JZ Wang, YQ Sun, XJ Huang. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer 2013; 119(5): 978–985
https://doi.org/10.1002/cncr.27761
pmid: 23097265
|
32 |
H Chen, S Ji, H Wang. A clinical study of haploidentical transplantation using granulocyte colony-stimulating factor stimulating donor bone marrow. Chin J Intern Med (Zhonghua Nei Ke Za Zhi) 2001; 40(11): 760–763 (in Chinese)
pmid: 11930684
|
33 |
SQ Ji, HR Chen, HX Wang, HM Yan, L Zhu, J Liu, M Xue, CQ Xun. G-CSF-primed haploidentical marrow transplantation without ex vivo T cell depletion: an excellent alternative for high-risk leukemia. Bone Marrow Transplant 2002; 30(12): 861–866
https://doi.org/10.1038/sj.bmt.1703769
pmid: 12476277
|
34 |
YJ Chang, Y Wang, XD Mo, XH Zhang, LP Xu, CH Yan, H Chen, YH Chen, Y Chen, W Han, FR Wang, JZ Wang, KY Liu, XJ Huang. Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: long-term outcomes of a prospective randomized trial. Cancer 2017; 123(15): 2881–2892
https://doi.org/10.1002/cncr.30540
pmid: 28301690
|
35 |
Y Wang, HX Fu, DH Liu, LP Xu, XH Zhang, YJ Chang, YH Chen, FR Wang, YQ Sun, FF Tang, KY Liu, XJ Huang. Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial. Bone Marrow Transplant 2014; 49(3): 426–433
https://doi.org/10.1038/bmt.2013.191
pmid: 24292519
|
36 |
Y Luo, H Xiao, X Lai, J Shi, Y Tan, J He, W Xie, W Zheng, Y Zhu, X Ye, X Yu, Z Cai, M Lin, H Huang. T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT. Blood 2014; 124(17): 2735–2743
https://doi.org/10.1182/blood-2014-04-571570
pmid: 25214441
|
37 |
H Fu, L Xu, D Liu, K Liu, X Zhang, H Chen, Y Chen, W Han, Y Wang, J Wang, F Wang, X Huang. Total body irradiation and cyclophosphamide plus antithymocyte globulin regimen is well tolerated and promotes stable engraftment as a preparative regimen before T cell-replete haploidentical transplantation for acute leukemia. Biol Blood Marrow Transplant 2014; 20(8): 1176–1182
https://doi.org/10.1016/j.bbmt.2014.04.012
pmid: 24747336
|
38 |
QF Liu, ZP Fan, Y Zhang, ZJ Jiang, CY Wang, D Xu, J Sun, Y Xiao, H Tan. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia. Biol Blood Marrow Transplant 2009; 15(11): 1376–1385
https://doi.org/10.1016/j.bbmt.2009.06.017
pmid: 19822296
|
39 |
QF Liu, ZP Fan, MQ Wu, J Sun, XL Wu, D Xu, QL Jiang, Y Zhang, F Huang, YQ Wei, J Zhao, GP Yu, FY Meng. Allo-HSCT for acute leukemia of ambiguous lineage in adults: the comparison between standard conditioning and intensified conditioning regimens. Ann Hematol 2013; 92(5): 679–687
https://doi.org/10.1007/s00277-012-1662-4
pmid: 23274355
|
40 |
L Xuan, Z Fan, Y Zhang, H Zhou, F Huang, M Dai, D Nie, D Lin, N Xu, X Guo, Q Jiang, J Sun, Y Xiao, Q Liu. Sequential intensified conditioning followed by prophylactic DLI could reduce relapse of refractory acute leukemia after allo-HSCT. Oncotarget 2016; 7(22): 32579–32591
https://doi.org/10.18632/oncotarget.8691
pmid: 27081039
|
41 |
R Zhang, W Shi, HF Wang, Y You, ZD Zhong, WM Li, C Zhang, X Lu, YD Wang, P Zheng, J Fang, M Hong, QL Wu, LH Xia. Idarubicin-intensified haploidentical HSCT with GvHD prophylaxis of ATG and basiliximab provides comparable results to sibling donors in high-risk acute leukemia. Bone Marrow Transplant 2017; 52(9): 1253–1260
https://doi.org/10.1038/bmt.2017.100
pmid: 28581464
|
42 |
Y Chen, Y Wang, LP Xu, KY Liu, H Chen, YH Chen, XH Zhang, FR Wang, W Han, JZ Wang, CH Yan, YY Zhang, YQ Sun, XJ Huang. Haploidentical stem cell transplantation in patients aged 50 yr and older with leukemia: similar outcomes compared to younger adults. Clin Transplant 2015; 29(6): 523–530
https://doi.org/10.1111/ctr.12545
pmid: 25809115
|
43 |
YQ Sun, LP Xu, XH Zhang, DH Liu, H Chen, Y Wang, CH Yan, JZ Wang, FR Wang, YY Zhang, KY Liu, XJ Huang. A retrospective comparison of BU-fludarabine and BU-CY regimens in elderly patients or in patients with comorbidities who received unmanipulated haploidentical hematopoietic SCT. Bone Marrow Transplant 2015; 50(4): 601–603
https://doi.org/10.1038/bmt.2014.303
pmid: 25599162
|
44 |
M Guo, KX Hu, CL Yu, QY Sun, JH Qiao, DH Wang, GX Liu, WJ Sun, L Wei, XD Sun, YJ Huang, JX Qiao, Z Dong, HS Ai. Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients. Blood 2011; 117(3): 936–941
https://doi.org/10.1182/blood-2010-06-288506
pmid: 20966170
|
45 |
X Zhao, F Gao, X Zhang, Y Wang, L Xu, K Liu, X Zhao, Y Chang, H Wei, H Chen, Y Chen, Z Jiang, X Huang. Improved clinical outcomes of rhG-CSF-mobilized blood and marrow haploidentical transplantation compared to propensity score-matched rhG-CSF-primed peripheral blood stem cell haploidentical transplantation: a multicenter study. Sci China Life Sci 2016; 59(11): 1139–1148
https://doi.org/10.1007/s11427-016-0014-8
pmid: 27535422
|
46 |
KH Lee, JH Lee, JH Lee, DY Kim, M Seol, YS Lee, YA Kang, M Jeon, HJ Hwang, AR Jung, SH Kim, SC Yun, HJ Shin. Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. Blood 2011; 118(9): 2609–2617
https://doi.org/10.1182/blood-2011-02-339838
pmid: 21715313
|
47 |
P Di Bartolomeo, S Santarone, G De Angelis, A Picardi, L Cudillo, R Cerretti, G Adorno, S Angelini, M Andreani, L De Felice, MC Rapanotti, L Sarmati, P Bavaro, G Papalinetti, M Di Nicola, F Papola, M Montanari, A Nagler, W Arcese. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood 2013; 121(5): 849–857
https://doi.org/10.1182/blood-2012-08-453399
pmid: 23165479
|
48 |
J Chen, RX Wang, F Chen, AN Sun, HY Qiu, ZM Jin, XW Tang, Y Han, ZZ Fu, GS He, M Miao, X Ma, DP Wu. Combination of a haploidentical SCT with an unrelated cord blood unit: a single-arm prospective study. Bone Marrow Transplant 2014; 49(2): 206–211
https://doi.org/10.1038/bmt.2013.154
pmid: 24141650
|
49 |
L Gao, Q Wen, X Chen, Y Liu, C Zhang, L Gao, P Kong, Y Zhang, Y Li, J Liu, Q Wang, Y Su, C Wang, S Wang, Y Zeng, A Sun, X Du, D Zeng, H Liu, X Peng, X Zhang. Effects of priming with recombinant human granulocyte colony-stimulating factor on conditioning regimen for high-risk acute myeloid leukemia patients undergoing human leukocyte antigen-haploidentical hematopoietic stem cell transplantation: a multicenter randomized controlled study in southwest China. Biol Blood Marrow Transplant 2014; 20(12): 1932–1939
https://doi.org/10.1016/j.bbmt.2014.08.001
pmid: 25109850
|
50 |
K Ikegame, T Yoshida, S Yoshihara, T Daimon, H Shimizu, Y Maeda, Y Ueda, K Kaida, S Ishii, K Taniguchi, M Okada, H Tamaki, H Okumura, H Kaya, T Kurokawa, Y Kodera, S Taniguchi, Y Kanda, H Ogawa. Unmanipulated haploidentical reduced-intensity stem cell transplantation using fludarabine, busulfan, low-dose antithymocyte globulin, and steroids for patients in non-complete remission or at high risk of relapse: a prospective multicenter phase I/II study in Japan. Biol Blood Marrow Transplant 2015; 21(8): 1495–1505
https://doi.org/10.1016/j.bbmt.2015.04.012
pmid: 25921715
|
51 |
SA Yahng, JH Kim, YW Jeon, JH Yoon, SH Shin, SE Lee, BS Cho, KS Eom, YJ Kim, S Lee, CK Min, SG Cho, DW Kim, JW Lee, WS Min, CW Park, HJ Kim. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia. Biol Blood Marrow Transplant 2015; 21(1): 119–129
https://doi.org/10.1016/j.bbmt.2014.09.029
pmid: 25300871
|
52 |
J Peccatori, A Forcina, D Clerici, R Crocchiolo, L Vago, MT Stanghellini, M Noviello, C Messina, A Crotta, A Assanelli, S Marktel, S Olek, S Mastaglio, F Giglio, L Crucitti, A Lorusso, E Guggiari, F Lunghi, M Carrabba, M Tassara, M Battaglia, A Ferraro, MR Carbone, G Oliveira, MG Roncarolo, S Rossini, M Bernardi, C Corti, M Marcatti, F Patriarca, M Zecca, F Locatelli, C Bordignon, K Fleischhauer, A Bondanza, C Bonini, F Ciceri. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia 2015; 29(2): 396–405
https://doi.org/10.1038/leu.2014.180
pmid: 24897508
|
53 |
WR Huang, HH Li, CJ Gao, J Bo, F Li, LP Dou, LL Wang, Y Jing, L Wang, DH Liu, L Yu. Haploidentical, unmanipulated G-CSF-primed peripheral blood stem cell transplantation for high-risk hematologic malignancies: an update. Bone Marrow Transplant 2016; 51(11): 1464–1469
https://doi.org/10.1038/bmt.2016.166
pmid: 27322853
|
54 |
H Long, ZG Lu, CY Song, YX Huang, JH Xu, JX Xu, L Deng, SF Tu, YZ He, X Lin, KY Guo, BY Wu. Long-term outcomes of HLA-haploidentical stem cell transplantation based on an FBCA conditioning regimen compared with those of HLA-identical sibling stem cell transplantation for haematologic malignancies. Bone Marrow Transplant 2016; 51(11): 1470–1475
https://doi.org/10.1038/bmt.2016.170
pmid: 27322852
|
55 |
T Yang, Q Lin, J Ren, P Chen, X Yuan, X Luo, T Liu, J Zheng, Z Zheng, X Zheng, X Chen, L Zhang, H Zheng, Z Chen, X Hua, S Le, J Li, Z Chen, J Hu. A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies. Oncotarget 2016; 7(48): 78773–78786
pmid: 27705929
|
56 |
JC Marsh, SE Ball, J Cavenagh, P Darbyshire, I Dokal, EC Gordon-Smith, J Keidan, A Laurie, A Martin, J Mercieca, SB Killick, R Stewart, JA Yin; British Committee for Standards in Haematology. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol 2009; 147(1): 43–70
https://doi.org/10.1111/j.1365-2141.2009.07842.x
pmid: 19673883
|
57 |
P Scheinberg, NS Young. How I treat acquired aplastic anemia. Blood 2012; 120(6): 1185–1196
https://doi.org/10.1182/blood-2011-12-274019
pmid: 22517900
|
58 |
LP Xu, KY Liu, DH Liu, W Han, H Chen, YH Chen, XH Zhang, Y Wang, FR Wang, JZ Wang, XJ Huang. A novel protocol for haploidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia. Bone Marrow Transplant 2012; 47(12): 1507–1512
https://doi.org/10.1038/bmt.2012.79
pmid: 22635243
|
59 |
LP Xu, SQ Wang, DP Wu, JM Wang, SJ Gao, M Jiang, CB Wang, X Zhang, QF Liu, LH Xia, X Wang, XJ Huang. Haplo-identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study. Br J Haematol 2016; 175(2): 265–274
https://doi.org/10.1111/bjh.14225
pmid: 27352174
|
60 |
Z Guo, HY Gao, TY Zhang, XD Liu, K Yang, JX Lou, XP He, Y Zhang, P Chen, HR Chen. Analysis of allogeneic hematopoietic stem cell transplantation with high-dose cyclophosphamide-induced immune tolerance for severe aplastic anemia. Int J Hematol 2016; 104(6): 720–728
https://doi.org/10.1007/s12185-016-2106-z
pmid: 27709450
|
61 |
S Kojima. Aplastic Anemia Treatment Guidelines of Asia-Pacific Hematology Consortium (APHCON). 2012.
|
62 |
SB Killick, N Bown, J Cavenagh, I Dokal, T Foukaneli, A Hill, P Hillmen, R Ireland, A Kulasekararaj, G Mufti, JA Snowden, S Samarasinghe, A Wood, JC Marsh; British Society for Standards in Haematology. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol 2016; 172(2): 187–207
https://doi.org/10.1111/bjh.13853
pmid: 26568159
|
63 |
M Wang, YJ Dong, ZX Qiu, MJ Wang, W Liu, LH Wang, Y Li, YH Sun, WL Xu, JP Ou, WS Wang, ZY Liang, Q Wang, XN Cen, HY Ren. HLA Disparity is not crucial for the survival rate and severity of chronic health conditions in adult recipients following family donor hematopoietic stem cell transplantation. Int J Hematol 2015; 101(1): 75–82
pmid: 25352358
|
64 |
MR Huo, LP Xu, D Li, DH Liu, KY Liu, H Chen, W Han, YH Chen, Y Wang, JZ Wang, XH Zhang, XY Zhao, XJ Huang. The effect of HLA disparity on clinical outcome after HLA-haploidentical blood and marrow transplantation. Clin Transplant 2012; 26(2): 284–291
https://doi.org/10.1111/j.1399-0012.2011.01499.x
pmid: 21919963
|
65 |
YJ Chang, XY Zhao, LP Xu, XH Zhang, Y Wang, W Han, H Chen, FR Wang, XD Mo, YY Zhang, MR Huo, XS Zhao, K y, KY Liu, XJ Huang. Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. J Hematol Oncol 2015; 8(1): 84
https://doi.org/10.1186/s13045-015-0182-9
pmid: 26156584
|
66 |
Y Wang, YJ Chang, LP Xu, KY Liu, DH Liu, XH Zhang, H Chen, W Han, YH Chen, FR Wang, JZ Wang, Y Chen, CH Yan, MR Huo, D Li, XJ Huang. Who is the best donor for a related HLA haplotype-mismatched transplant? Blood 2014; 124(6): 843–850
https://doi.org/10.1182/blood-2014-03-563130
pmid: 24916508
|
67 |
XY Zhao, YJ Chang, XS Zhao, LP Xu, XH Zhang, KY Liu, D Li, XJ Huang. Recipient expression of ligands for donor inhibitory KIRs enhances NK-cell function to control leukemic relapse after haploidentical transplantation. Eur J Immunol 2015; 45(8): 2396–2408
https://doi.org/10.1002/eji.201445057
pmid: 25952732
|
68 |
Y Wang, QF Liu, LP Xu, KY Liu, XH Zhang, X Ma, ZP Fan, DP Wu, XJ Huang. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood 2015; 125(25): 3956–3962
https://doi.org/10.1182/blood-2015-02-627786
pmid: 25940714
|
69 |
Y Wang, HX Wang, YR Lai, ZM Sun, DP Wu, M Jiang, DH Liu, KL Xu, QF Liu, L Liu, JB Wang, F Gao, J Ou-Yang, SJ Gao, LP Xu, XJ Huang. Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant. Leukemia 2016; 30(10): 2055–2063
https://doi.org/10.1038/leu.2016.110
pmid: 27133816
|
70 |
Y Wang, QF Liu, LP Xu, KY Liu, XH Zhang, X Ma, MQ Wu, DP Wu, XJ Huang. Haploidentical versus matched-sibling transplant in adults with Philadelphia-negative high-risk acute lymphoblastic leukemia: a biologically phase III randomized study. Clin Cancer Res 2016; 22(14): 3467–3476
https://doi.org/10.1158/1078-0432.CCR-15-2335
pmid: 26927664
|
71 |
XH Luo, YJ Chang, LP Xu, DH Liu, KY Liu, XJ Huang. The impact of graft composition on clinical outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic SCT. Bone Marrow Transplant 2009; 43(1): 29–36
https://doi.org/10.1038/bmt.2008.267
pmid: 18776927
|
72 |
XY Zhao, YJ Chang, LP Xu, DH Liu, KY Liu, XJ Huang. Association of natural killer cells in allografts with transplant outcomes in patients receiving G-CSF-mobilized PBSC grafts and G-CSF-primed BM grafts from HLA-haploidentical donors. Bone Marrow Transplant 2009; 44(11): 721–728
https://doi.org/10.1038/bmt.2009.73
pmid: 19377516
|
73 |
YJ Chang, LP Xu, Y Wang, XH Zhang, H Chen, YH Chen, FR Wang, W Han, YQ Sun, CH Yan, FF Tang, XD Mo, KY Liu, XJ Huang. Controlled, randomized, open-label trial of risk-stratified corticosteroid prevention of acute graft-versus-host disease after haploidentical transplantation. J Clin Oncol 2016; 34(16): 1855–1863
https://doi.org/10.1200/JCO.2015.63.8817
pmid: 27091717
|
74 |
H Ning, F Yang, M Jiang, L Hu, K Feng, J Zhang, Z Yu, B Li, C Xu, Y Li, J Wang, J Hu, X Lou, H Chen. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 2008; 22(3): 593–599
https://doi.org/10.1038/sj.leu.2405090
pmid: 18185520
|
75 |
L Gao, Y Zhang, B Hu, J Liu, P Kong, S Lou, Y Su, T Yang, H Li, Y Liu, C Zhang, L Gao, L Zhu, Q Wen, P Wang, X Chen, J Zhong, X Zhang. Phase II multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord-derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem-cell transplantation. J Clin Oncol 2016; 34(24): 2843–2850
https://doi.org/10.1200/JCO.2015.65.3642
pmid: 27400949
|
76 |
CH Yan, LP Xu, FR Wang, H Chen, W Han, Y Wang, JZ Wang, KY Liu, XJ Huang. Causes of mortality after haploidentical hematopoietic stem cell transplantation and the comparison with HLA-identical sibling hematopoietic stem cell transplantation. Bone Marrow Transplant 2016; 51(3): 391–397
https://doi.org/10.1038/bmt.2015.306
pmid: 26691421
|
77 |
XJ Huang, DH Liu, KY Liu, LP Xu, H Chen, W Han. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007; 92(3): 414–417
https://doi.org/10.3324/haematol.10570
pmid: 17339194
|
78 |
XJ Huang, DH Liu, KY Liu, LP Xu, YH Chen, Y Wang, W Han, H Chen. Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia. J Clin Immunol 2008; 28(3): 276–283
https://doi.org/10.1007/s10875-007-9166-z
pmid: 18204965
|
79 |
XD Mo, XH Zhang, LP Xu, Y Wang, CH Yan, H Chen, YH Chen, W Han, FR Wang, JZ Wang, KY Liu, XJ Huang. Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes. Eur J Haematol 2016; 96(3): 297–308
https://doi.org/10.1111/ejh.12591
pmid: 26010204
|
80 |
CH Yan, Y Wang, JZ Wang, YH Chen, Y Chen, FR Wang, YQ Sun, XD Mo, W Han, H Chen, XH Zhang, LP Xu, KY Liu, XJ Huang. Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant. J Hematol Oncol 2016; 9(1): 87
https://doi.org/10.1186/s13045-016-0319-5
pmid: 27629395
|
81 |
CH Yan, DH Liu, KY Liu, LP Xu, YR Liu, H Chen, W Han, Y Wang, YZ Qin, XJ Huang. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 2012; 119(14): 3256–3262
https://doi.org/10.1182/blood-2011-09-380386
pmid: 22337715
|
82 |
S Anguille, E Lion, Y Willemen, VF Van Tendeloo, ZN Berneman, EL Smits. Interferon-a in acute myeloid leukemia: an old drug revisited. Leukemia 2011; 25(5): 739–748
https://doi.org/10.1038/leu.2010.324
pmid: 21274002
|
83 |
X Mo, X Zhao, L Xu, D Liu, X Zhang, H Chen, Y Wang, X Huang. Interferon a: the salvage therapy for patients with unsatisfactory response to minimal residual disease-directed modified donor lymphocyte infusion. Chin Med J (Engl) 2014; 127(14): 2583–2587
pmid: 25043071
|
84 |
XD Mo, XH Zhang, LP Xu, Y Wang, CH Yan, H Chen, YH Chen, W Han, FR Wang, JZ Wang, KY Liu, XJ Huang. Interferon-a: a potentially effective treatment for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2015; 21(11): 1939–1947
https://doi.org/10.1016/j.bbmt.2015.06.014
pmid: 26116088
|
85 |
CH Yan, QF Liu, DP Wu, X Zhang, LP Xu, XH Zhang, Y Wang, H Huang, H Bai, F Huang, X Ma, XJ Huang. Prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease and graft-versus-host disease-guided multiple DLIs could improve outcomes after allogeneic hematopoietic stem cell transplantation in patients with refractory/relapsed acute leukemia. Biol Blood Marrow Transplant 2017; 23(8): 1311–1319
https://doi.org/10.1016/j.bbmt.2017.04.028
pmid: 28483716
|
86 |
Y Sun, F Meng, M Han, X Zhang, L Yu, H Huang, D Wu, H Ren, C Wang, Z Shen, Y Ji, X Huang. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study. Biol Blood Marrow Transplant 2015; 21(6): 1117–1126
https://doi.org/10.1016/j.bbmt.2015.03.018
pmid: 25840339
|
87 |
X Jiang, L Xu, Y Zhang, F Huang, D Liu, J Sun, C Song, X Liang, Z Fan, H Zhou, M Dai, C Liu, Q Jiang, N Xu, L Xuan, M Wu, X Huang, Q Liu. Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation. OncoImmunology 2016; 5(5): e1139274
https://doi.org/10.1080/2162402X.2016.1139274
pmid: 27467959
|
88 |
LP Xu, S Jin, SQ Wang, LH Xia, H Bai, SJ Gao, QF Liu, JM Wang, X Wang, M Jiang, X Zhang, DP Wu, XJ Huang. Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant. J Hematol Oncol 2017; 10(1): 25
https://doi.org/10.1186/s13045-017-0398-y
pmid: 28107815
|
89 |
XD Mo, XY Zhao, DH Liu, YH Chen, LP Xu, XH Zhang, H Chen, W Han, Y Wang, FR Wang, JZ Wang, KY Liu, XJ Huang. Umbilical cord blood transplantation and unmanipulated haploidentical hematopoietic SCT for pediatric hematologic malignances. Bone Marrow Transplant 2014; 49(8): 1070–1075
https://doi.org/10.1038/bmt.2014.109
pmid: 24887381
|
90 |
SO Ciurea, UD Bayraktar. “No donor”? Consider a haploidentical transplant. Blood Rev 2015; 29(2): 63–70
https://doi.org/10.1016/j.blre.2014.09.009
pmid: 25307958
|
91 |
MT Rubio, BN Savani, M Labopin, S Piemontese, E Polge, F Ciceri, A Bacigalupo, W Arcese, Y Koc, D Beelen, Z Gülbas, D Wu, S Santarone, J Tischer, B Afanasyev, C Schmid, S Giebel, M Mohty, A Nagler. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT. J Hematol Oncol 2016; 9(1): 25
https://doi.org/10.1186/s13045-016-0248-3
pmid: 26980295
|
92 |
N Santoro, A Ruggeri, M Labopin, A Bacigalupo, F Ciceri, Z Gülbaş, H Huang, B Afanasyev, W Arcese, D Wu, Y Koc, J Tischer, S Santarone, S Giebel, M Mohty, A Nagler. Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. J Hematol Oncol 2017; 10(1): 113
https://doi.org/10.1186/s13045-017-0480-5
pmid: 28558762
|
93 |
S Piemontese, F Ciceri, M Labopin, W Arcese, S Kyrcz-Krzemien, S Santarone, H Huang, D Beelen, NC Gorin, C Craddock, Z Gulbas, A Bacigalupo, M Mohty, A Nagler; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia. J Hematol Oncol 2017; 10(1): 24
https://doi.org/10.1186/s13045-017-0394-2
pmid: 28103944
|
94 |
A Bashey, MJ Zhang, SR McCurdy, A St Martin, T Argall, C Anasetti, SO Ciurea, O Fasan, S Gaballa, M Hamadani, P Munshi, MM Al Malki, R Nakamura, PV O’Donnell, MA Perales, K Raj, R Romee, S Rowley, V Rocha, RB Salit, M Solh, RJ Soiffer, EJ Fuchs, M Eapen. Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell-replete haploidentical donor transplantation using post-transplant cyclophosphamide. J Clin Oncol 2017; 35(26): 3002–3009
https://doi.org/10.1200/JCO.2017.72.8428
pmid: 28644773
|
95 |
A Mancusi, L Ruggeri, E Urbani, A Pierini, MS Massei, A Carotti, A Terenzi, F Falzetti, A Tosti, F Topini, S Bozza, L Romani, R Tognellini, M Stern, F Aversa, MF Martelli, A Velardi. Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality. Blood 2015; 125(20): 3173–3182
https://doi.org/10.1182/blood-2014-09-599993
pmid: 25769621
|
96 |
R Handgretinger. Haploidentical transplantation: the search for the best donor. Blood 2014; 124(6): 827–828
https://doi.org/10.1182/blood-2014-06-582460
pmid: 25104858
|
97 |
JR Passweg, H Baldomero, P Bader, C Bonini, RF Duarte, C Dufour, A Gennery, N Kröger, J Kuball, F Lanza, S Montoto, A Nagler, JA Snowden, J Styczynski, M Mohty. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant 2017; 52(6): 811–817
https://doi.org/10.1038/bmt.2017.34
pmid: 28287639
|
98 |
R Champlin. Now everyone has a donor for HSCT. Blood 2011; 118(2): 218
https://doi.org/10.1182/blood-2011-05-352518
pmid: 21757626
|
99 |
Y Wang, DP Wu, QF Liu, LP Xu, KY Liu, XH Zhang, Y Xu, F Huang, XJ Huang. Donor and recipient age, gender and ABO incompatibility regardless of donor source: validated criteria for donor selection for haematopoietic transplants. Leukemia 2018; 32(2): 492–498
https://doi.org/10.1038/leu.2017.199
pmid: 28642591
|
100 |
S Piemontese, F Ciceri, M Labopin, A Bacigalupo, H Huang, S Santarone, NC Gorin, Y Koc, D Wu, D Beelen, J Tischer, G Ehninger, W Arcese, A Nagler, M Mohty; Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT). A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia. Leukemia 2015; 29(5): 1069–1075
https://doi.org/10.1038/leu.2014.336
pmid: 25434302
|
101 |
F Locatelli, P Merli, D Pagliara, G Li Pira, M Falco, D Pende, R Rondelli, B Lucarelli, LP Brescia, R Masetti, GM Milano, V Bertaina, M Algeri, RM Pinto, L Strocchio, R Meazza, L Grapulin, R Handgretinger, A Moretta, A Bertaina, L Moretta. Outcome of children with acute leukemia given HLA-haploidentical HSCT after ab T-cell and B-cell depletion. Blood 2017; 130(5): 677–685
https://doi.org/10.1182/blood-2017-04-779769
pmid: 28588018
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|